Bevacizumab

• Metastatic Colorectal Cancer: 5 mg/kg or 10 mg/kg every 2 weeks, depending on the chemotherapy regimen.
• Non-Small Cell Lung Cancer: 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.
• Glioblastoma: 10 mg/kg every 2 weeks as a single agent.
• Metastatic Renal Cell Carcinoma: 10 mg/kg every 2 weeks in combination with interferon alfa.
• Cervical Cancer: 15 mg/kg every 3 weeks in combination with chemotherapy.
• Ovarian Cancer: 15 mg/kg every 3 weeks in combination with chemotherapy, or as per specific treatment protocols.

• Known hypersensitivity to Bevacizumab or any component of the formulation.
• Recent history of significant bleeding or hemorrhage.
• Recent surgery or significant wounds that have not healed, as Bevacizumab can impair wound healing.
• Untreated central nervous system (CNS) metastases, due to the risk of CNS bleeding.

• Report any unusual symptoms, such as severe headaches, dizziness, chest pain, or signs of bleeding (e.g., nosebleeds, coughing up blood), to their healthcare provider immediately.
• Be aware of the increased risk of high blood pressure (hypertension) and monitor their blood pressure regularly during treatment.
• Avoid elective surgery or dental procedures without consulting their healthcare provider, as Bevacizumab can impair wound healing.
• Inform their healthcare provider if they are pregnant or planning to become pregnant, as Bevacizumab can cause harm to the fetus.
• Attend all scheduled follow-up appointments and imaging studies to monitor the effectiveness and safety of the treatment.

• High blood pressure (hypertension)
• Fatigue or weakness
• Diarrhea
• Abdominal pain
• Nausea and vomiting
• Loss of appetite
• Mouth sores

• Bleeding: Including gastrointestinal bleeding, nosebleeds, or hemorrhage in the brain.
• Blood Clots: Such as deep vein thrombosis (DVT), pulmonary embolism, or stroke.
• Gastrointestinal Perforation: A rare but serious complication involving a hole in the stomach or intestines.
• Wound Healing Complications: Delayed healing or wound dehiscence (reopening of a surgical wound).
• Nephrotic Syndrome: A kidney condition leading to proteinuria and swelling.
• Infusion Reactions: Including fever, chills, and difficulty breathing during the infusion.

• Bleeding Risk: Bevacizumab increases the risk of bleeding, including serious and potentially fatal hemorrhages. Patients with a history of bleeding disorders or those receiving anticoagulant therapy should be closely monitored.
• Hypertension: Bevacizumab can cause significant increases in blood pressure. Patients should have their blood pressure monitored regularly, and antihypertensive treatment may be required.
• Gastrointestinal Perforation: Although rare, Bevacizumab can cause gastrointestinal perforation, which is a life-threatening condition requiring immediate medical attention.
• Impaired Wound Healing: Bevacizumab can impair wound healing, so it should be discontinued before elective surgery and not resumed until wounds have healed.
• Proteinuria: Bevacizumab can cause proteinuria, which may indicate kidney damage. Regular urine tests are recommended during treatment.

• Anticoagulants: Such as warfarin or heparin, which can increase the risk of bleeding when used with Bevacizumab.
• Antihypertensives: May be needed to manage the increased blood pressure associated with Bevacizumab.
• Other Anti-Angiogenic Agents: Concurrent use with other VEGF inhibitors may increase the risk of adverse effects such as bleeding or hypertension.

• Other Anti-Angiogenic Agents: Such as ramucirumab (Cyramza), which also targets VEGF and is used in similar types of cancer.
• Targeted Therapies: Such as cetuximab (Erbitux) for colorectal cancer, or pembrolizumab (Keytruda) for non-small cell lung cancer, depending on the specific cancer type and genetic markers.
• Chemotherapy: Different chemotherapy regimens depending on the type and stage of cancer.
• Radiation Therapy: In some cases, radiation may be used in conjunction with or instead of targeted therapies.

The choice of treatment depends on the specific type of cancer, its stage, and the patient’s overall health and response to previous treatments.